Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard Total International Bond Index Fund ETF (BNDX) vs ClearPoint Neuro Inc (CLPT) Price & Performance

Vanguard Total International Bond Index Fund ETFTrade
ClearPoint Neuro IncTrade

Price performance (Past 24H)

Key statistics

Vanguard Total International Bond Index Fund ETF vs ClearPoint Neuro Inc — how do they compare? Vanguard Total International Bond Index Fund ETF trades at $47.83, while ClearPoint Neuro Inc trades at $14.75 (market cap $454.21M). The key difference: ClearPoint Neuro Inc is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.

BNDXCLPT
52-Week High
$49.91$29.60
52-Week Low
$47.57$8.66
Market Cap
$454.21M
Sector
Health
Enterprise Value
$488.79M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Total International Bond Index Fund ETF

BNDX trades at $47.91, up 0.25% with neutral technical signals. The ETF shows mixed institutional activity with Apella Capital reducing holdings by 3.0% while Archer Investment increased by 48.2% in Q2 2026. Recent dividend payments of $0.11-$0.12 provide income appeal, though key valuation ratios remain unavailable for analysis.

Outlook remains balanced amid bond market volatility. Rising Treasury yields and inflation concerns create headwinds, while institutional interest and steady dividends offer support. The ETF's international bond exposure provides diversification benefits but remains sensitive to global interest rate movements and geopolitical tensions.

ClearPoint Neuro Inc

ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.

The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.

Returns comparison

Trailing returns across standard periods

About Vanguard Total International Bond Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.

Read more on BNDX

About ClearPoint Neuro Inc

ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.

Read more on CLPT